Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 9/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.49 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077295 | 0.85 | HDAC6 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL595353 | 0.85 | HDAC6 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10045893 | 0.84 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2884335 | 0.80 | PTGS2 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15914501 | 0.79 | TRAP1 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14714191 | 0.79 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15928914 | 0.78 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19341436 | 0.78 | HDAC3 (0.45) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15914502 | 0.78 | TRAP1 (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL15928865 | 0.77 | PTGS2 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7879827-B2 | such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer | ANTIBE THERAPEUTICS INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-7879827-B2 | such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer | ANTIBE THERAPEUTICS INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | HDAC3 863/4885HDAC4 223/4885HDAC1 462/4885 |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | CBS, SI, TST | HDAC3 745/4885HDAC4 157/4885HDAC1 353/4885 |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | HDAC3 863/4885HDAC4 223/4885HDAC1 462/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | HDAC3 863/4885HDAC4 223/4885HDAC1 462/4885 |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | CBS, SI, APC | HDAC3 863/4885HDAC4 223/4885HDAC1 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.